Ann: Positive FDA Pre-IND meeting guides IHL-42X development, page-25

Anybody know if there will be a marked difference in how potential acquirers would view results from a pivotal phase II study versus the proof of concept study IHL has already done? I get that it further de-risks it but I mean, we've already demonstrated efficacy in humans with the target indication which is the whole point of a phase II, and I would imagine is the main de-risking aspect big pharma is looking for.